Shire sells skin substitute Dermagraft, takes $650 million hit
LONDON (Reuters) – Pharmaceuticals company Shire has agreed to sell its Dermagraft treatment to U.S. group Organogenesis, taking a $650 million hit on the loss-making bio-engineered skin substitute it bought less than three years ago. Shire had hoped that Dermagraft would be the foundation of a regenerative medicine franchise when its acquired owner Advanced BioHealing […]